Concord Biotech: Intimation of allotment of Bonus equity s hare s
Concord Biotech (CONCORDBIO) filed a disclosure titled "Intimation of allotment of Bonus equity s hare s". The company is valued at about ₹7,038 crore.
What happened
Concord Biotech (CONCORDBIO) filed a disclosure with the exchanges on 5 November 2026 at 06:03 PM titled "Intimation of allotment of Bonus equity s hare s".
From the filing: "Consequent to the aforesaid allotment, paid - up share capital of the Company stands increased to Rs. 20,92,32,408 / - divided into 20,92,32,408 fully paid - up equity shares of Rs. 1/ - each."
How big is it?
At ₹20.92 crore, the issue is equal to about 0.3% of the company's market value of ₹7,038 crore.
Company snapshot
Concord Biotech is a small-cap company in the Healthcare sector, with a market value of about ₹7,038 crore.
The stock last traded at ₹672.7, against a 52-week range of ₹493.5–₹1,513 (55.5% below the high).
Before this filing the shares had moved −10.6% over the month and −13.5% over three months. Average daily turnover over the last 20 sessions was about ₹8.79 crore.
Promoters held 44.09% at the end of Q2 FY27, up 0.01% points from the previous quarter. Foreign institutions owned 7.28% and domestic institutions 10.95%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 247 | 63.6 | 6.03 |
| Q3 FY26 | 278 | 64.5 | 6.08 |
| Q4 FY26 | 326 | 88.8 | 8.46 |
| Q1 FY27 | 257 | 58.5 | 5.52 |
| Q2 FY27 | 309 | 70.7 | 6.65 |
What history shows
BCEIE has no earlier fund raising filing from this company on record since May 2026.
Across 34 similar disclosures by other Healthcare companies, shares moved +0.8% on average the next day and +0.9% over five days; 56% of them rose the next day.
Market-wide, 1,733 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
In the news
Recent coverage elsewhere (links open the original publisher):
- Concord Biotech Bonus Issue 2026: Company fixes record date for 1:1 bonus shares
- Concord Biotech Qtrly Consol Net Profit 706.5 Mln Rupees
- Concord Biotech posts double-digit profit growth in Q2, but margins take a hit
- Concord Biotech Limited says expansion cut H1 margin by 480 bps
- Concord Biotech Ltd (NSE:CONCORDBIO) (Q2 2027) Earnings Call Highlights: 25% Revenue Surge, ...
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.